Intensity Therapeutics, Inc. 8-K Filing

FAQ

Key Financial Figures

• $0.0001 — nge on Which Registered: Common Stock, $0.0001 par value per share INTS The Nasdaq Sto
• $1.00 — maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing

Filing Documents

• intensity-20251204.htm (8-K) — 33KB
• ints20251208ex99120251205n.htm (EX-99.1) — 14KB
• image01.jpg (GRAPHIC) — 4KB
• 0001567264-25-000111.txt ( ) — 180KB
• intensity-20251204.xsd (EX-101.SCH) — 2KB
• intensity-20251204_lab.xml (EX-101.LAB) — 23KB
• intensity-20251204_pre.xml (EX-101.PRE) — 13KB
• intensity-20251204_htm.xml (XML) — 3KB

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on June 6, 2025, Intensity Therapeutics, Inc. (the "Company") received a letter (the "June 2025 Nasdaq Letter") from The Nasdaq Stock Market ("Nasdaq") notifying the Company that for the preceding 30 consecutive business days the Company's common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on Nasdaq (the "Minimum Bid Price Requirement"). The June 2025 Nasdaq Letter stated that the Company had 180 calendar days, or until December 3, 2025 (the "Initial Compliance Date"), to demonstrate compliance with the Minimum Bid Price Requirement. On December 4, 2025, the "Company received a second letter (the "December 2025 Nasdaq Letter") from Nasdaq stating that the Company is eligible for an additional 180 calendar days, or until June 1, 2026, to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). The Staff of the Nasdaq (the "Staff") determined that the Company is eligible for the second 180 calendar day period, or until June 1, 2026, to regain compliance with the Rule based on the Staff's determination that the Company must continue to meet the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this additional time period, the closing bid price of the Company's common stock on the Nasdaq is at least $1.00 per share for a minimum of ten (10) consecutive business days, the Staff will provide written confirmation of compliance with the

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued Dec ember 5 , 2025. 104 Cover Page Interactive Data File (formatted in Inline XBRL). CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Comments in this Current Report on Form 8-K and in the exhibit attached hereto contain certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which are based on management's good faith expectations and beliefs concerning future developments. Actual results may differ materially from these expectations as a result of many factors. These factors include, but are not limited to, the risks and uncertainties described in the "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements" sections of the Company's Annual Report on Form 10-K, filed on March 13, 2025, the Company's Quarterly Report on Form 10-Q, filed on May 13, 2025, the Company's Quarterly Report on Form 10-Q, filed on August 7, 2025, and the Company's Quarterly Report on 1 Form 10-Q, filed on November 6, 2025. The Company does not undertake any obligation to update such forward-looking statements. All market and industry data are based on Company estimates. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 5, 2025 Intensity Therapeutics, Inc. By: /s/ Lewis H. Bender Name: Lewis H. Bender Title: Chief Executive Officer [ Signature Page to the Form 8-K ] 3

View Full Filing

View this 8-K filing on SEC EDGAR